Business Context and Reporting Period
Compugen Ltd. (NASDAQ: CGEN), an Israeli biotechnology company focused on the discovery and licensing of therapeutic and diagnostic product candidates, reported financial results for the second quarter ended June 30, 2006. The company operates a discovery engine to identify novel proteins and peptides for cancer, autoimmune, and cardiovascular diseases, with a commercialization strategy centered on milestone and revenue-sharing licensing agreements.
Key Financial Metrics
| Metric | Q2 2006 | Q2 2005 | YTD 6 Months 2006 | YTD 6 Months 2005 |
|---|---|---|---|---|
| Revenues | $5,000 | $70,000 | $205,000 | $551,000 |
| Net Loss | $(3.62) million | $(3.34) million | $(6.71) million | $(7.08) million |
| Loss Per Share | $(0.13) | $(0.12) | $(0.24) | $(0.25) |
| R&D Expenses (Net of Grants) | $2.87 million | $2.66 million | $5.19 million | $5.76 million |
| Cash and Equivalents (Total) | $30.4 million | N/A | N/A | N/A |
Liquidity and Balance Sheet: As of June 30, 2006, total assets were $35.6 million, down from $42.1 million at year-end 2005. Total cash, cash equivalents, long-term deposits, and marketable securities totaled $30.4 million. Total current liabilities were $2.0 million, and total long-term liabilities were $1.6 million. The company reported no debt obligations in the provided text.
Material Changes vs. Prior Period
- Revenue Decline: Q2 2006 revenue dropped to $5,000 from $70,000 in Q2 2005. YTD revenue decreased to $205,000 from $551,000.
- Net Loss: Q2 net loss increased slightly to $3.62 million from $3.34 million. However, YTD net loss improved to $6.71 million compared to $7.08 million in the prior year.
- Expense Reduction: Net R&D expenses decreased YTD by approximately $570,000, driven by lower gross R&D spend and a reduction in governmental grants ($522,000 in 2006 vs. $788,000 in 2005).
- Cash Burn: Total cash and marketable securities decreased by $6.4 million over the six-month period.
Outlook, Risks, and Management Commentary
Management Commentary: CEO Alex Kotzer highlighted progress in the commercial roadmap, noting the initiation of biological validation for five potential therapeutic molecules selected from approximately seventy candidates. The company is also advancing diagnostic activities with partners evaluating over ten biomarkers for cancer and cardiovascular diseases.
Guidance: Compugen anticipates receiving milestone and revenue-sharing payments from existing arrangements by the end of 2006 or early 2007, with substantial revenue increases expected in subsequent years as products progress toward commercialization.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include changes in collaborator relationships, competitive product impacts, technological development risks, and the ability to retain customers. The company remains dependent on successful milestone attainment by partners for future revenue.
Investor Verification Checklist
- Verify the status of the five therapeutic molecules currently undergoing biological validation.
- Confirm the timeline and probability of milestone payments from existing licensing partners expected by late 2006 or early 2007.
- Assess the sustainability of the current cash burn rate ($6.4 million over six months) against the $30.4 million cash position.
- Review the specific terms of the diagnostic collaborations regarding the ten biomarkers under evaluation.
- Monitor the impact of reduced governmental grants on future R&D expense management.